Exceptionally rare for cyclones to happen in Indonesia, says researcherpublished at 05:34 GMT
Arie Firdaus
BBC Indonesian
The widespread flooding and landslides hitting Indonesia over the past few days have been triggered by Cyclone…
Author: admin
-
Asia extreme weather: Ninety dead in Indonesia floods as cyclone displaces thousands in Sri Lanka
Exceptionally rare for cyclones to happen in Indonesia, says researcherpublished at 05:34 GMT
-
How Patrick Kavanagh’s immortal poem On Raglan Road was lost and then found – The Irish Times
It’s unusual, if not rare, for a work by an acclaimed poet to appear in the pages of a national newspaper, only for it to vanish without trace, then resurface, 18 years later, and go on to become one of Ireland’s greatest poems.
The poet was
Continue Reading
-
5 Fast Facts Our New Cell based Flu Vaccine and Antivenom Manufacturing Facility in Australia
With the opening of its new high-tech vaccine manufacturing facility at Tullamarine, CSL Seqirus is turning the page.
The site near Melbourne Airport includes three buildings and will have a gross floor area of 28,400m2, larger than the playing surface of the famous Melbourne Cricket Ground. The facility has been electrified and incorporates on-site solar energy generation, heat and water recovery to preserve a healthier environment.
“This facility will build a platform for our next wave of innovation in vaccines and unique health challenges, setting a new standard of care,” said CSL Seqirus Managing Director Dave Ross, who will be on hand for the 2 December opening celebration.
Globally, the World Health Organization estimates that seasonal flu infects 1 billion people annually, causing severe illness in 3-5 million and 290,000-650,000 respiratory deaths.
Here are five facts about the new site, built to protect public health:
- It is the only manufacturing facility of its kind in the Southern Hemisphere.
- Considered modern, efficient and highly scalable, cell-based influenza vaccine manufacturing advances scalability, reduces reliance on large volumes of critical materials and enables rapid production of vaccines using state-of-the-art technology. That makes it well suited to pandemic preparedness. With year-round seasonal flu vaccine manufacturing, the Tullamarine facility will be ever ready to switch over to pandemic response.
- It features a digitally connected manufacturing environment, deploying advanced analytics that will drive innovation and optimise manufacturing operations. This includes a fully automated and paperless manufacturing execution system that will support our highly skilled workforce to optimise production, conduct predictive maintenance, improve quality control and reduce downtime.
- Tullamarine will support a supply chain worth $300 million with hundreds of experts on hand to ensure that essential vaccines and antivenoms reach the clinics and patients who need them.
- It will be the only manufacturing site in the world capable of producing Australia’s 11 antivenoms for venomous creatures and the human Q-Fever vaccine.
Continue Reading
-
Australia names unchanged squad for second Ashes test against England next week in Brisbane
BRISBANE, Australia (AP) — Leading 1-0 in the five-test Ashes series after a stunning two-day win in the first test at Perth, Australia has named an unchanged squad for the day-night second match at the Gabba in Brisbane starting Dec. 4.
Captain…
Continue Reading
-
Ricoh recognized as a Prime Seat Company in the 2025 Nikkei SDGs Management Grand Prix | Global
Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support digital transformation of workplaces, workspaces and optimize business performance.
Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organizational capabilities nurtured over its 85-year history. In the financial year ended March 2025, Ricoh Group had worldwide sales of 2,527 billion yen (approx. 16.8 billion USD).
It is Ricoh’s mission and vision to empower individuals to find Fulfillment through Work by understanding and transforming how people work so we can unleash their potential and creativity to realize a sustainable future.
For further information, please visit
###
© 2025 RICOH COMPANY, LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.
Continue Reading
-
Dynamics of postnatal upper airway bacteria colonization in preterm infants
Hou, K. et al. Microbiota in health and diseases. Signal Transduct. Target. Ther. 7, 135 (2022).
Aguilar-Lopez, M., Dinsmoor, A. M., Ho, T. T. B. & Donovan, S. M. A systematic review of the factors influencing microbial colonization of the preterm infant gut. Gut Microbes 13, 1–33 (2021).
DeVeaux, A., Ryou, J., Dantas, G., Warner, B. B. & Tarr, P. I. Microbiome-targeting therapies in the neonatal intensive care unit: safety and efficacy. Gut Microbes 15, 2221758 (2023).
Staude, B. et al. The microbiome and preterm birth: a change in paradigm with profound implications for pathophysiologic concepts and novel therapeutic strategies. Biomed. Res. Int. 2018, 7218187 (2018).
Bårdsen, T. et al. Impaired lung function in extremely preterm-born adults in their fourth decade of life. Am. J. Respir. Crit. Care Med. 208, 493–495 (2023).
Islam, J. Y., Keller, R. L., Aschner, J. L., Hartert, T. V. & Moore, P. E. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 192, 134–156 (2015).
Bårdsen, T. et al. Tracking of lung function from 10 to 35 years after being born extremely preterm or with extremely low birth weight. Thorax 77, 790–798 (2022).
Lee, D. M. X., Tan, A. K. S., Ng, Y. P. M. & Amin, Z. Quality of life of patients and caregivers affected by bronchopulmonary dysplasia: a systematic review. Qual. Life Res. 32, 1859–1869 (2023).
Horbar, J. D. et al. Trends in mortality and morbidities for infants born 24 to 28 weeks in the US: 1997–2021. Pediatrics 153, e2023064153 (2024).
Holzfurtner, L. et al. When inflammation meets lung development-an update on the pathogenesis of bronchopulmonary dysplasia. Mol. Cell Pediatr. 9, 7 (2022).
Pammi, M. et al. Airway microbiome and development of bronchopulmonary dysplasia in preterm infants: a systematic review. J.Pediatr. 204, 126-133.e2 (2019).
Young, K. C., Del Moral, T., Claure, N., Vanbuskirk, S. & Bancalari, E. The association between early tracheal colonization and bronchopulmonary dysplasia. J. Perinatol. 25, 403–407 (2005).
Mourani, P. M., Harris, J. K., Sontag, M. K., Robertson, C. E. & Abman, S. H. Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants. PloS one 6, e25959 (2011).
Ehrhardt, H. et al. Mode of delivery and incidence of bronchopulmonary dysplasia: results from the population-based EPICE cohort. Neonatology 119, 464–473 (2022).
Staude, B. et al. Microbial signatures in amniotic fluid at preterm birth and association with bronchopulmonary dysplasia. Respir. Res. 24, 248 (2023).
Lauer, T. et al. Bacterial Colonization within the First Six Weeks of Life and Pulmonary Outcome in Preterm Infants <1000 g. J. Clin. Med. 9, 2240 (2020).
Rofael, S. A. D. et al. Airway microbiome in adult survivors of extremely preterm birth: the EPICure study. The European respiratory journal 53 (2019).
Dolma, K. et al. Effects of hyperoxia on alveolar and pulmonary vascular development in germ-free mice. Am. J. Physiol. Lung Cell.Mol. physiol. 318, L421–L428 (2020).
Dong, Y. et al. Insights into the black box of intra-amniotic infection and its impact on the premature lung: from clinical and preclinical perspectives. Int. J. Mol. Sci. 23, 9792 (2022).
Shrestha, A. K. et al. Consequences of early postnatal lipopolysaccharide exposure on developing lungs in mice. Am. J. physiol. Lung cell. Mol. Physiol. 316, L229–L244 (2019).
Shrestha, A. K. et al. Interactive and independent effects of early lipopolysaccharide and hyperoxia exposure on developing murine lungs. Am. J. physiol. Lung cell. Mol. Physiol. 319(L981), L996 (2020).
Huang, J. et al. Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch. Dis. Child Fetal Neonatal. Ed. 104, F128–F136 (2019).
Köstlin-Gille, N. et al. Early initiation of antibiotic therapy and short-term outcomes in preterm infants: a single-centre retrospective cohort analysis. Arch. Dis. Child. Fetal Neonatal Ed. 108(623), 630 (2023).
Romijn, M. et al. Prediction models for bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. J. Pediatr. 258, 113370 (2023).
Christoph J et al. Risikocharakterisierung Intensivmedizinisch Behandelter Früh- Und Neugeborener Und Daten Zur Ist-Situation in Deutschen Neonatologischen Intensivpflegestationen 2013 – Fachliche Erläuterungen Zu Folgender Empfehlung: Praktische Umsetzung Sowie Krankenhaushygienische Und Infektionspräventive Konsequenzen Des Mikrobiellen Kolonisationsscreenings Bei Intensivmedizinisch Behandelten Früh- Und Neugeborenen Ergänzende Empfehlung Der Kommission Für Krankenhaushygiene Und Infektionsprävention (KRINKO) Beim Robert Koch-Institut, Berlin Zur Implementierung Der Empfehlungen Zur Prävention Nosokomialer Infektionen Bei Neonatologischen Intensivpflegepatienten Mit Einem Geburtsgewicht Unter 1.500 g Aus Dem Jahr 2007 Und 2012. 42 (Epidemiologisches Bulletin des Robert Koch-Instituts, Berlin, 2013).
Parm, U. et al. Risk factors associated with gut and nasopharyngeal colonization by common gram-negative species and yeasts in neonatal intensive care units patients. Early Hum. Dev. 87, 391–399 (2011).
Sgro, M. et al. Early-onset neonatal sepsis: rate and organism pattern between 2003 and 2008. J. Perinatol. : Off. J. California Perinat. Assoc. 31, 794–798 (2011).
Kaufman, D. & Fairchild, K. D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin. Microbiol. Rev. 17, 638–80 (2004).
Joubert, I. A., Otto, M., Strunk, T. & Currie, A. J. Look who’s talking: host and pathogen drivers of staphylococcus epidermidis virulence in neonatal sepsis. Int. J. Mol. Sci. 23, 860 (2022).
Davis, E. C. et al. Gut microbiome and breast-feeding: Implications for early immune development. J.Allergy Clin. Immunol. 150, 523–534 (2022).
Thiess, T. et al. Correlation of early nutritional supply and development of bronchopulmonary dysplasia in preterm infants <1,000 g. Front. Pediatr. 9, 741365 (2021).
Voigt, M., Schneider, K. T. M. & Jährig, K. Analyse des Geburtengutes des Jahrgangs 1992 der Bundesrepublik Deutschland [Analysis of a 1992 birth sample in Germany. 1: New percentile values of the body weight of newborn infants]. Geburtshilfe Frauenheilkd 56, 550–558 (1996).
Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723–1729 (2001).
Fawke, J. et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am. J. Respire. Crit. Care Med. 182, 237–245 (2010).
Walter, S. D., Feinstein, A. R. & Wells, C. K. Coding ordinal independent variables in multiple regression analyses. Am. J. Epidemiol. 125, 319–323 (1987).
Wood, S. N. Generalized Additive Models: An Introduction with R, Second Edition. (Chapman and Hall/CRC, New York). https://doi.org/10.1201/9781315370279. (2017)
Gertheiss, J., Scheipl, F., Lauer, T. & Ehrhardt, H. Statistical inference for ordinal predictors in generalized additive models with application to bronchopulmonary dysplasia. BMC Res. Notes 15, 112 (2022).
Hothorn, T., Hornik, K. & Zeileis, A. Unbiased recursive partitioning: a conditional inference framework. J. Comput. Graphical Stat. 15, 651–674 (2006).
Strobl, C., Boulesteix, A.-L., Kneib, T., Augustin, T. & Zeileis, A. Conditional variable importance for random forests. BMC Bioinform. 9, 307 (2008).
R Core Team. R: A Language and Environment for Statistical Computing. (2023).
Rückle, X. et al. Different probiotic strains alter human cord blood monocyte responses. Pediatr. Res. 94, 103–111 (2023).
Samara, J. et al. Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host Microbe 30, 696-711.e5 (2022).
Elazab, N. et al. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. Pediatrics 132, e666-76 (2013).
Collins, J. J. P. et al. Repeated intrauterine exposures to inflammatory stimuli attenuated transforming growth factor-\textgreekb signaling in the ovine fetal lung. Neonatology 104, 49–55 (2013).
Azizia, M., Lloyd, J., Allen, M., Klein, N. & Peebles, D. Immune status in very preterm neonates. Pediatrics 129, e967-74 (2012).
Schmidt, B., Roberts, R., Millar, D. & Kirpalani, H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 93, 284–287 (2008).
Brewer, M. R. et al. Determinants of the lung microbiome in intubated premature infants at risk for bronchopulmonary dysplasia. J. Maternal-fetal Neonatal Med.:Official J. Euro. Assoc. Perinat. Med. Federation Asia Oceania Perinat. Soc. Int. Soc. Perinat. Obstetricians 34, 3220–3226 (2021).
Strobel, N. A., Adams, C., McAullay, D. R. & Edmond, K. M. 2022 Mother’s own milk compared with formula milk for feeding preterm or low birth weight infants: systematic review and meta-analysis. Pediatrics 150,= (2022).
Vatne, A. et al. Early empirical antibiotics and adverse clinical outcomes in infants born very preterm: a population-based cohort. J. Pediatr. 253, 107-114.e5 (2023).
Batta, V. K., Rao, S. C. & Patole, S. K. Bifidobacterium infantis as a probiotic in preterm infants: a systematic review and meta-analysis. Pediatr. Res. 94, 1887–1905 (2023).
Villamor-Martínez, E. et al. Probiotic supplementation in preterm infants does not affect the risk of bronchopulmonary dysplasia: a meta-analysis of randomized controlled trials. Nutrients 9, 1197 (2017).
Beck, L. C. et al. Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. Nat. Microbiol. 7, 1525–1535 (2022).
Wang, Y. et al. Probiotics, prebiotics, lactoferrin, and combination products for prevention of mortality and morbidity in preterm infants: a systematic review and network meta-analysis. JAMA Pediatr. 177, 1158–1167 (2023).
Martí, M. et al. Effects of Lactobacillus reuteri supplementation on the gut microbiota in extremely preterm infants in a randomized placebo-controlled trial. Cell Rep. Med. 2, 100206 (2021).
Hoshiyar, A. ordPens: an R package for selection, smoothing and principal components analysis for ordinal variables. J. Open Source Softw. 6, 3828 (2021).
Continue Reading
-
Scientists detect 'micro-lightning' on Mars for first time – news.cgtn.com
- Scientists detect ‘micro-lightning’ on Mars for first time news.cgtn.com
- Detection of triboelectric discharges during dust events on Mars Nature
- Blue, green and even turquoise — Lights in motion spotted in Mars’s sky El Diario 24
- Scientists…
Continue Reading
-
Rapid growth of US tax-minimising ETFs draws scrutiny
Billions of dollars are flowing into US exchange traded funds designed primarily as tax-minimising vehicles, in a move that is drawing criticism from politicians and which some in the industry believe could attract the attention of tax authorities.
A number of fund firms have been creating ETFs that either lower the interest or dividend income that can be taxed, or alternatively reduce capital gains tax on investors’ pre-existing stock portfolios.
The latter type is proving the most contentious. Known as section 351 or ETF swap funds, they are designed specifically to help investors with large portfolios who would face a significant tax bill if they sold holdings that had risen in value. At least seven such funds managing $2.2bn have launched this year, with four more currently being seeded.
“Everybody is looking at this creatively, which is great, but it then also makes you wonder sometimes how far is too far,” said Brittany Christensen, head of business development at Tidal Financial Group, which manages $50bn of assets and has several 351 funds among its near-300 ETFs.
Some US politicians are already opposing these funds. In June, Ron Wyden, the top Democrat on the Senate finance committee, put forward legislation that would prevent tax-free transfers of appreciated securities to 351 funds.
Jeffrey Colon, professor of law at Fordham University School of Law, said that, unless Congress acts, tax paid by publicly traded investment vehicles would “inevitably” decline.
“The Wyden proposal is a necessary and appropriate first step in reining in the newest tax abuse of ETFs,” he said. “The growing popularity of ETFs and recent launches of ETF swap funds requires a new urgency.”
“The government is clearly aware of these issues, but so far has not indicated any inclination to attack them. The investment company lobby is very powerful,” he added.
ETFs have always been more tax efficient than more traditional mutual funds in the US, due to a quirk in the tax system. Whereas mutual funds often trigger a capital gains tax event when they sell profitable positions, ETFs can usually avoid doing so by trading “in kind” with market makers, so that no cash changes hands.
Three decades on from the birth of ETFs, though, some issuers are looking to turbocharge this tax efficiency. The less contentious funds minimise coupon or dividend income — subject to income tax — by switching holdings shortly before payments fall due.
In August Washington DC-based F/m Investments launched the F/m Compoundr High Yield Bond ETF and F/m Compoundr US Aggregate Bond ETF. The two funds invest in bond ETFs but then rotate into other ETFs just before each underlying fund’s ex-dividend date, “converting monthly interest income into unrealised capital gains”, according to the firm. This strategy also minimises withholding taxes for non-US investors.
Roundhill Investments and LionShares have launched similar funds that invest in equity funds.
While the extent to which investors will take advantage of these tax loopholes remains to be seen, some funds are already delivering savings.
The Alpha Architect 1-3 Month Box ETF, known as BOXX, which invests in options to mimic an ultra-short duration bond portfolio, has had net flows of $8.6bn since launch and now holds $9bn of assets, implying it has made a total return of $400mn. Assuming investors would have paid the highest rate of interest income tax but instead pay the long-term capital gains tax rate of 20 per cent, this would translate into a tax saving of $68mn, according to Financial Times calculations.
“This is a significant trend because taxes are often top of mind for investors and ETFs have found ways to manage tax exposures,” said Bryan Armour, director of passive strategies research in North America at Morningstar.
Section 351 funds — named after a previously little-used section in the US Internal Revenue Code — are seen by some as upping the ante still further. Contributing their pre-existing shareholdings allows wealthy investors to convert them into shares in an ETF, without triggering a capital gain.
Tidal’s Christensen said the Internal Revenue Service might have some concerns over people contributing stock they received as part of an employee share plan. That is particularly the case if they are slicing this stock up into several 351 conversions in order to ensure they contribute a diversified portfolio, which is required under US tax rules, to each ETF.
“At what point does the IRS start to look into this and say we are giving this to people who have had a compensation equity plan?” she said. “This is a new use case for section 351. It makes you wonder if it started to raise some red flags.”
Fund firm Exchange Traded Concepts has conducted a number of such launches, with “several billion dollars more” in the pipeline, according to chief executive Garrett Stevens.
He added that several have been for family offices “that have their own assets, but they are going ‘why wouldn’t we do what we do inside the more tax-advantaged tax wrapper?’”
Stevens said similar arrangements already exist for holders of real estate and annuity contracts, allowing them to rotate positions without incurring tax.
“It’s not unique. It’s an IRS rule,” he said. “It’s all legal, we are not skirting any regulations. There are probably a lot of unintended consequences in tax legislation.”
But Elisabeth Kashner, director of global fund analytics at FactSet, said this strategy, coupled with other aspects of tax law used by the wealthy, “is certainly not honouring the intention of the tax code. It’s not playing by the consensus of how we run this country.”
She added: “From a tax fairness point of view the investor has brilliantly avoided taxes and has had access to a good portion of his or her assets, and everyone else in the country has been deprived of that money for the Treasury.”
Continue Reading
-
Targeting tumor metabolic flexibility enhances radiotherapeutic efficacy via mitochondrial complex I Inhibition in an intracranial S180 sarcoma mouse model
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144 (5), 646–674 (2011).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York) 324 (5930), 1029–1033 (2009).
Warburg, O. On the Origin of Cancer Cells Vol. 123, p. 309–314 (Science, 1956). 3191.
Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer. 11 (5), 325–337 (2011).
Jose, C., Bellance, N. & Rossignol, R. Choosing between Glycolysis and oxidative phosphorylation: a tumor’s dilemma? Biochim. Biophys. Acta. 1807 (6), 552–561 (2011).
Bonnet, S. et al. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11 (1), 37–51 (2007).
Greene, J., Segaran, A. & Lord, S. Targeting OXPHOS and the electron transport chain in cancer; molecular and therapeutic implications. Sem. Cancer Biol. 86 (Pt 2), 851–859 (2022).
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 21 (3), 297–308 (2012).
Pavlova, N. N. & Thompson, C. B. The Emerg. Hallm. Cancer Metabolism Cell. Metabolism, 23(1): 27–47. (2016).
Dang, C. V. MYC on the path to cancer. Cell 149 (1), 22–35 (2012).
Zong, W. X., Rabinowitz, J. D. & White, E. Mitochondria Cancer Mol. Cell., 61(5): 667–676. (2016).
Sancho, P. et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metabol. 22 (4), 590–605 (2015).
Vlashi, E. & Pajonk, F. Cancer stem cells, cancer cell plasticity and radiation therapy. Sem. Cancer Biol. 31, 28–35 (2015).
Fendt, S. M., Frezza, C. & Erez, A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 10 (12), 1797–1807 (2020).
Kreuzaler, P. et al. Adapt and conquer: metabolic flexibility in cancer growth, invasion and evasion. Mol. Metabolism, 33. 83-101 (2020). doi:10.1016/j.molmet.2019.08.021
Bailleul, J. & Vlashi, E. Glioblastomas: Hijacking Metabolism To Build a Flexible Shield for Therapy Resistance Vol. 39, p. 957–979 (Antioxidants & Redox Signaling, 2023). 13–15.
Obre, E. & Rossignol, R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int. J. Biochem. Cell Biol. 59, 167–181 (2015).
Yang, B. & Shi, J. Chemistry of Advanced Nanomedicines in Cancer Cell Metabolism Regulation. Adv. Sci. (Weinheim Baden-Wurttemberg Germany). 7 (18), p2001388 (2020).
Luo, Z. et al. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett. 575, 216396 (2023).
Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11, 9-15 (2015). doi:10.1038/nchembio.1712
Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an achilles’ heel? Nat. Rev. Cancer. 14 (11), 709–721 (2014).
Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 4 (6), 437–447 (2004).
Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer. 6 (8), 583–592 (2006).
Vlashi, E. et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl. Acad. Sci. U.S.A. 108 (38), 16062–16067 (2011).
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23 (10), 1124–1134 (2017).
Janiszewska, M. et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 26 (17), 1926–1944 (2012).
Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514 (7524), 628–632 (2014).
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24 (7), 1036–1046 (2018).
Baran, N. et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat. Commun. 13 (1), 2801 (2022).
Zhou, Y. et al. Recent advances of mitochondrial complex I inhibitors for cancer therapy: current status and future perspectives. Eur. J. Med. Chem. 251, 115219 (2023).
Al Assi, A. et al. A novel inhibitor of the mitochondrial respiratory complex I with uncoupling properties exerts potent antitumor activity. Cell Death Dis. 15 (5), 311 (2024).
Basit, F. et al. Mitochondrial complex I Inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis. 8 (3), e2716 (2017).
Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat. Med. 29 (1), 115–126 (2023).
Tufail, M., Jiang, C. H. & Li, N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol. Cancer. 23 (1), 203 (2024).
Gao, X. et al. Inhibition of Mitochondria NADH-Ubiquinone Oxidoreductase (complex I) Sensitizes the Radioresistant Glioma U87MG Cells To Radiation Vol. 129, p. 110460 (Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2020).
Hess-Stumpp, H. J. C. R. Abstract LB-244: BAY 87-2243, an inhibitor of HIF-1α-induced gene activation, showed promising anti-tumor efficacy in combination with anti-angiogenic therapy and irradiation in preclinical tumor models. Cancer Res. 72 (8_Supplement), LB-244-LB-244 (2012).
Ashton, T. M. et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Research: Official J. Am. Association Cancer Res. 24 (11), 2482–2490 (2018).
Liu, Z. et al.Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an Intracranial Sarcoma Mouse Model. Vaccines 11 (7), (2023).
Tran, T. A. T. et al. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus Irinotecan in a glioblastoma mouse model. Front. Immunol. 13, 1009484 (2022).
Smilowitz, H. M. et al. Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunol. Immunotherapy: CII. 65 (2), 127–139 (2016).
Lan, X. Y. et al. Unlocking the potential of Ultra-High dose fractionated radiation for effective treatment of glioblastoma in mice. J. Cancer. 15 (13), 4060–4071 (2024).
Zarghami, N. et al. Half brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response. Radiation Oncol. (London England). 13 (1), 104 (2018).
Zanoni, M. et al. Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma. Cell Death Dis. 13 (1), 80 (2022).
Jin, L. et al. The ROS/AKT/S6K axis induces corneal epithelial dysfunctions under LED blue light exposure. Ecotoxicol. Environ. Saf. 287, 117345 (2024).
Jiang, J. et al. Catechin Promotes Endoplasmic Reticulum stress-mediated Gastric Cancer Cell Apoptosis Via NOX4-induced Reactive Oxygen Species (Molecular and Cellular Biochemistry, 2024).
DeBerardinis, R. J. et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol. 7 (1), 11–20 (2008).
Zong, Y. et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal. Transduct. Target. Therapy. 9 (1), 124 (2024).
Raimondi, V., Ciccarese, F. & Ciminale, V. Oncogenic pathways and the electron transport chain: a DangeROS liaison. Br. J. Cancer. 122 (2), 168–181 (2020).
Perillo, B. et al. ROS in cancer therapy: the bright side of the Moon. Exp. Mol. Med. 52 (2), 192–203 (2020).
Dosunmu-Ogunbi, A. M. et al. Decoding the role of SOD2 in sickle cell disease. Blood Adv. 3 (17), 2679–2687 (2019).
Bastin, J. et al. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration. J. Translational Med. 21 (1), 522 (2023).
Hubackova, S. et al. Mitochondria-driven elimination of cancer and senescent cells. Biol. Chem. 400 (2), 141–148 (2019).
Martínez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11 (1), 102 (2020).
Martell, E. et al. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 Medulloblastoma. Nat. Commun. 14 (1), 2502 (2023).
Zhang, Z. et al. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target. EBioMedicine 89, 104483 (2023).
Ivashkevich, A. et al. Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 327 (1–2), 123–133 (2012).
Guo, C. et al. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regeneration Res. 8 (21), 2003–2014 (2013).
Borodkina, A. et al. Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging 6 (6), 481–495 (2014).
Stiff, T. et al. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64 (7), 2390–2396 (2004).
Alarifi, S. et al. Regulation of apoptosis through bcl-2/bax proteins expression and DNA damage by nano-sized gadolinium oxide. Int. J. Nanomed. 12, 4541–4551 (2017).
Kalkavan, H. & Green, D. R. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 25 (1), 46–55 (2018).
Chipuk, J. E. & Green, D. R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18 (4), 157–164 (2008).
Wang, C. & Youle, R. J. The role of mitochondria in apoptosis*. Annu. Rev. Genet., 43. 95-118 (2009). doi:10.1146/annurev-genet-102108-134850
Vyas, S., Zaganjor, E. & Haigis, M. C. Mitochondria Cancer Cell., 166(3): 555–566. (2016).
Porter, A. G. & Jänicke, R. U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ., 6, 99-104 (1999). doi:10.1038/sj.cdd.4400476
Ferreira, K. S. et al. Caspase-3 feeds back on caspase-8, bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis: Int. J. Program. Cell. Death. 17 (5), 503–515 (2012).
Diepart, C. et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 72 (2), 482–490 (2012).
Park, Y. Y. et al. ATP Depletion during Mitotic Arrest Induces Mitotic Slippage and APC/CCdh1-dependent Cyclin B1 Degradation Vol. 50 (Experimental & Molecular Medicine, 2018). 4.
Hoeijmakers, J. H. J. DNA damage, aging, and cancer. N. Engl. J. Med. 361 (15), 1475–1485 (2009).
Sancar, A. et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39–85 (2004).
McCann, E., O’Sullivan, J. & Marcone, S. Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response. Translational Oncol. 14 (1), 100905 (2021).
Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29 (5), 946–960 (2022).
Zheng, X. X. et al. Mitochondria in cancer stem cells: Achilles heel or hard armor. Trends Cell Biol. 33 (8), 708–727 (2023).
Fan, M. et al. Cancer stem cell fate determination: mito-nuclear communication. Cell. Communication Signaling: CCS. 21 (1), 159 (2023).
Fleury, C., Mignotte, B. & Vayssière, J. L. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 84 (2–3), 131–141 (2002).
Stine, Z. E. et al. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21 (2), 141–162 (2022).
Xu, Y. et al. Why all the fuss about oxidative phosphorylation (OXPHOS)? J. Med. Chem. 63 (23), 14276–14307 (2020).
Continue Reading
-
Japan’s Two-Year Bond Sale Demand Weaker Than 12-Month Average – Bloomberg.com
- Japan’s Two-Year Bond Sale Demand Weaker Than 12-Month Average Bloomberg.com
- Japanese government bonds edge lower ahead of 40-year debt auction Business Recorder
- Benchmark JGB yields rise on issuance shuffle; 2-year notes stable before auction TradingView
- Japan’s 40-Year Bond Sale Demand Slightly Higher Than Average Bloomberg.com
- JGB Yields Higher After Strong Tokyo Inflation Data The Wall Street Journal
Continue Reading